The patents are valid through 2029, 2030 and 2028 respectively, said the company's press release.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, that are being developed for cognitive disorders with high unmet medical needs, having a huge market potential globally," said Mr Venkat Jasti, CEO, Suven.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents, useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington's disease, Parkinson's and Schizophrenia.
With these new patents, Suven now totally has seventeen granted patents from New Zealand, sixteen from Singapore and eleven from South Korea. Products out of these inventions is expected to be out-licensed at various phases of clinical development, that is, at Phase-I or Phase-II.